Macrophage-targeting nano-formulated bicalutamide alleviates colitis by inducing MAP3K1-mediated degradation of NLRP3.
Zhong S, Zhong S, Wu Y, Liu Z, Yang Y, Wang X, Li S, Wu Y, Huang X, Zhu Y, Zhou Z, Xu Y, Wen L, Yao X.
Zhong S, et al. Among authors: yao x.
J Control Release. 2025 Jan 30:S0168-3659(25)00086-0. doi: 10.1016/j.jconrel.2025.01.076. Online ahead of print.
J Control Release. 2025.
PMID: 39892647